]>
IRCT2017013032236N2 IRCT 2017-02-20 Vice chancellor for research, Mazandaran University of Medical Sciences Memantine effect in the treatment of residual symptoms in patients with schizophrenia Study of the efficacy and safety of memantine as an adjuvant to antipsychotics on improving positive and negative symptoms in patients with residual schizophrenia 2017-02-01 anticipated 50 Complete https://irct.ir/trial/25159 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: This is a randomized double-blind controlled study. The participants and assessor are aware of neither drugs nor placebo. The block randomization method is used . 2-3 Schizophrenia. Intervention 1: Subjects in the intervention group receive memantine with an initial dose of 10 mg/day for first week, which is increased to 20 mg/day on the second week and continue with the same dose until the end of the study along with their antipsychotic regimen for 8 weeks . Intervention 2: The control group receive their antipsychotic regimen with placebo for eight weeks.
public Dr Narjes Hendouei
Department of Pharmacotherapy, Faculty of Pharmacy,Mazandaran University of Medical Sciences
Sari Iran (Islamic Republic of) +98 11 3354 3081 hendoieen@yahoo.com Mazandaran University of Medical Sciences scientific Dr Narjes Hendouei
Department of Pharmacotherapy, Faculty of Pharmacy,Mazandaran University of Medical Sciences
Sari Iran (Islamic Republic of) +98 11 3354 3081 hendoieen@yahoo.com Mazandaran University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: 1- Male or female are recruited from in-patient units in yahyaneghad hospital located in Babol in the north of Iran 2- 18–65 years at the time of screening 3- With a diagnosis of schizophrenia(paranoid, disorganized, catatonic, or undifferentiated type)or schizoaffective disorder, based on the Structured Clinical Interview for DSM-V and they are suffering from the disease for more than 2 years with residual symptomatology despite antipsychotic treatment 4- All patients are on antipsychotics for at least 1 year and a stable dose for at least 2 month are included in the trial and the antipsychotics dose remain unchanged during the trial. 5- Mood stabilizers (lithium and divalproex) and antidepressants (only the selective serotonine reuptake inhibitors (SSRIs) venlafaxine, and mirtazapine) were permitted as part of antipsychotic pharmacotherapy. Dose of these drugs must be stable for at least 2 month remain unchanged during the trial. Exclusions criteria: 1- Acute relapse (As acute relapse was defined an impending decompensation based on a PANSS score of ≥4 (moderately) on the subscore items of hostility and uncooperativeness and/or a ≥20% increase in the PANSS total score. 2- Psychiatric comorbidity(primary or secondary diagnosis of bipolar I disorder, either manic or mixed episode, as defined by DSM-V) 3- History of substance dependence (including alcohol, but excluding nicotine) as defined by DSM-V and relapse within the past 6 months, or substance abuse within the 3 months preceding the trial or positive urine test for illicit drugs 4- Electroconvulsive therapy during the 6 past months 5- Suicidality(active suicide or homicide intent, or a suicide or homicide attempt in the preceding 6 months) 6- Mental retardation 7- Pregnant or at risk of pregnancy 8- Cognitive disorders such as dementia, delirium, or amnesia, traumatic brain injury 9- Current significant unstable medical illness (such as unstable cardiac disease, hepatic or renal impairment, evidence or history of malignancy or any significant hematological, endocrine)/ HIV infection / abnormalities on physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory values 10- Hypersensitivity to memantine 11- Previous treatment with memantine in the past year 12- History of neuroleptic malignant syndrome 13- Patients under treatment cholinesterase inhibitors, N-methyl D-aspartate (NMDA) receptor antagonists 14- Unwilling or unable, in the opinion of the Investigator, to comply with study instructions 18 years 65 years Both F20 F20.5 Treatment - Drugs Placebo Subjects in the intervention group receive memantine with an initial dose of 10 mg/day for first week, which is increased to 20 mg/day on the second week and continue with the same dose until the end of the study along with their antipsychotic regimen for 8 weeks . The control group receive their antipsychotic regimen with placebo for eight weeks. Severity of psychiatric symptoms assesment. Timepoint: Baseline and weeks 3, 6 and 8. Method of measurement: Positive and Negative Syndrome Scale (PANSS). Depressed mood assessment. Timepoint: Baseline and weeks 3, 6 and 8. Method of measurement: Calgary Depression Scale for Schizophrenia. Severity and type of obsessive compulsive symptoms assessment. Timepoint: Baseline and weeks 3, 6 and 8. Method of measurement: Yale–Brown Obsessive Compulsive Scale. Clinical Global Impression of Improvement (CGI-S). Timepoint: Baseline and weeks 3, 6 and 8. Method of measurement: Clinical Global Impression of Improvement (CGI-S). Clinical Global Impression of Improvement (CGI-I). Timepoint: Baseline and weeks 3, 6 and 8. Method of measurement: Clinical Global Impression of Improvement (CGI-I). Nigella sativa induced akathisia assessment. Timepoint: Weekly. Method of measurement: Barnes Akathisia Scale. Nigella sativa induced Movement disorder assessment. Timepoint: Weekly. Method of measurement: Abnormal Involuntary Movement Scale. - - Vice chancellor for research, Mazandaran University of Medical Sciences Approved 2016-09-22 Ethics committee of Mazandaran University of Medical Sciences Moallem street-Moallem square-Vice chancellor for research , Mazandaran University of Medical Sciences Sari Iran (Islamic Republic of)